The present teachings relate to a separator that uses density differences to fractionate a suspension such as blood.
Clinicians have identified a wide range of therapeutic and laboratory applications for autologous isolated fractions, such as platelet concentrate, platelet-poor-plasma, and stromal cells, of suspensions such as blood, bone marrow aspirate, and adipose tissue. Clinicians generally prefer to draw and fractionate the autologous suspension at the point-of-care. Point-of-care fractionation can reduce the need for multiple appointments to draw and fractionate the autologous suspension which can be costly and inconvenient. Additionally, point-of-care preparation reduces potential degradation of the autologous suspension that can begin once the autologous suspension is removed from a patient. Point-of-care fractionation systems should be easy to operate to reduce the need to provide clinicians with extensive instruction, quick so the therapeutic fraction can be isolated and administered during a single patient visit, efficient to effectively isolate the fraction to a desired concentration, and reproducible to operate over wide variations in suspension characteristics. An example of a buoy based suspension fractionation system is shown in Biomet Biologics, Inc. international brochure entitled “Gravitational Platelet Separation System Accelerating the Body's Natural Healing Process,” 2006.
A buoy suspension fractionation system comprises a separation container and a buoy. The separation container defines a volume enclosed by a container wall, a container bottom, a container top and an access port to access the volume. The buoy is carried in the separation container and has a tuned density that is configured to reach an equilibrium position in a suspension. The buoy comprises a buoy upper surface and a buoy sidewall defining a height, a transverse dimension, and a perimeter. The buoy further comprises a guide surface and a collection space above the buoy upper surface. The guide surface is carried on the buoy upper surface and is inclined to an accumulation position near the buoy perimeter. The buoy suspension fractionation system can be used in a method of isolating a fraction from a suspension, and in a method for isolating a fraction and re-suspending isolated particulates for withdrawal.
The present teachings will become more fully understood from the detailed description and the accompanying drawings, wherein:
FIG. 9A1 is a plan view of a buoy at a selected transverse plane;
FIG. 9A2 is a plan view of a buoy at a selected transverse plane;
Isolated fractions can be used in a variety of clinical applications, animal applications, and laboratory applications. Some of the clinical applications include peripheral vascular disease, orthopedic surgery, plastic surgery, oral surgery, cardio-thoracic surgery, brain and neural procedures, and wound healing. Laboratory applications include isolating, creating or synthesizing therapeutic materials or materials for analysis from fractions produced by the fractionation system.
Although the fractionation system 10 can be used allogeneically, such as with pooled blood, the fractionation system 10 can be used autologously to reduce risks of potential incompatibility and contamination with pathogenic diseases. Also, other autologous materials can be used including cerebrospinal fluid, cerebrospinal fluid can be obtained via a spinal tap or other appropriate collection procedure. A general description of a fractionation system is provided in a Biomet Biologics, Inc. international brochure “Gravitation Platelet Separation System Accelerating the Body's Natural Healing Process” (2006) and a description of a therapeutic procedure using platelet concentrate is shown in a Biomet Biologics, Inc. international brochure “Shoulder Recovery with the GPS® Platelet Concentration System” (2004), incorporated herein by reference.
It will be understood that the buoy 30 can be altered depending upon the material placed in the container 12. For example, if neural stem cells are to be separated from cerebrospinal fluid then the buoy 30 can have a density to allow collection of the neural stem cells in the collection area 52 of the system 12. The collected neural stem cells can also be applied for therapeutic reasons or used in laboratory study, isolation, culture, etc.
Returning reference to
The various ports 22, 26 and 27 can be provided to allow access to any appropriate compartment of the container 12. The access ports 22, 26, 27 can be any means that allow communication from outside the separation container 12 to the separation container volume 21 such as a Luer lock port, a septum, a valve, or other opening. The container vent 31 allows movement of air between the inside and outside the separation container 12 to equalize pressure when suspension in introduced into or withdrawn from the separation container 12. The container vent 31 can include a vent filter 31a to serve as a sterile barrier to allow air to enter the separation container 12 while preventing undesired materials from entering the separation container 12.
When the separation container 12 is at rest, a buoy perimeter 30a and the container wall 16 can be dimensioned to form an interference fit to hold the buoy 30 at a position in the separation container 12. When the separation container 12 is centrifuged, the buoy perimeter 30a and the container wall 16 have clearance allowing the buoy 30 to move within the separation container 12 and a material to pass between the buoy perimeter 30a and the container wall 16. For example, the container 12 can compress axially to increase its internal diameter. Alternatively, the buoy 30 could have an opening (e.g.
The buoy 30 is carried in the separation container 12 and has a tuned density that is configured to reach a selected equilibrium position in a suspension. The buoy can have its density tuned in the range from about 1.0 g/cc to about 1.10 g/cc, such as about 1.06 g/cc. The buoy 30, according to various embodiments, can be formed to include the tuned density and can be formed of one or more materials to achieve the tuned density.
For example, the density of about 1.06 g/cc can position the buoy 30, or a selected part of the buoy 30 including the collection area 52, at an equilibrium position of a buffy coat of a separated whole blood sample. In a further example, the density can also be tuned so that the collection area 52 is near an equilibrium position, such as where neural stem cells collect in a selected suspension. Regardless of the density of the buoy 30, it can be selected to position the buoy 30 at an equilibrium position of a selected material.
As illustrated in
The buoy comprises a buoy upper surface 48 and a buoy sidewall 38, 40 defining a height H1, H2, a transverse dimension at planes A1, A2, and a perimeter 30a, discussed further herein. The buoy further comprises a guide surface 42. In some embodiments, the buoy can further comprise a collection port 50 and a precision collection region 44. The collection port 50 communicates with the access port 27 and communicates with a collection space 52 above the buoy upper surface 42 and can be located near the buoy perimeter 30a. In some embodiments, the collection port 50 is not carried on the buoy, but rather the collection port is a withdraw device such as a syringe that is inserted through an access port or top of the tube 12.
With reference to
The guide surface 42 is carried on and/or defined by the buoy upper surface 48 and is inclined to an accumulation position at or near the buoy perimeter. The guide surface 42 serves as a guide means for conveying particles down an incline toward an equilibrium interface or collection region. The guide surface 42 can be inclined relative to the buoy sidewall 38 height for a distance of more than one-half the buoy transverse dimension or width W1, such as about two-thirds the buoy transverse dimension, and in various embodiments the guide surface can be inclined relative to the buoy sidewall 38 substantially throughout a length of the guide surface 42.
The guide surface 42 can be substantially planar and can have an average angle in the range from the minimum for particulates to move down the guide surface, regarding blood platelets, for example, about 10 degrees to about 60 degrees. For example, angle can be about 5 degrees to about 89 degrees, or greater, including about 30 degrees to about 89 degrees. Angle can, exemplary, be exactly or about 60 degrees in various embodiments. In some embodiments, the guide surface can include contours defined in the guide surface with multiple angles such as shown in
In various embodiments, as exemplary illustrated in
In use, the substantially maximum transverse cross-sectional area W1 of the buoy 30 can be positioned at a selected location. As illustrated in FIG. 9A1, the maximum cross-sectional area is at plane A1. The plane A1 can be positioned at or near a selected equilibrium interface, in use. The position of the plane A1 is selected by selecting a density of the buoy 30 and the known or estimated density of the material into which the buoy 30 is positioned. The buoy's maximum transverse cross-sectional area near the intended or selected interface results in a substantially maximum change in displacement of the relative volume of a fraction below the equilibrium interface and substantially maximum change in displacement of a fraction above the equilibrium interface relative to change in the axial orientation of the buoy relative to the interface. This can improve fractionation isolation by ensuring that the maximum transverse cross-section displaces a maximum amount of area within the container 12 at the selected interface. For example, more than 90% of a whole blood's platelets can be isolated.
Thus, in applications involving suspensions, such as whole blood, which may be variable in composition between samples, sample density variation will result in minimal variation in the axial orientation of the buoy relative to a selected equilibrium interface. The minimal variation in axial location of the buoy 30 in the container 12 is based at least in part on the maximum displacement of a material in the container at the maximum transverse cross-section of the buoy 30. In other words, for each small variation of axial location of the buoy 30, a maximum displacement occurs. In selected uses, the buoy's maximum cross-sectional plane A1 is provided at a selected location and the minimal axial variation helps to ensure the plane A1 is properly placed.
Additionally, at or near the buoy's maximum transverse cross-sectional area, the cross-sectional area of the fractionated material is near minimal. Simply, within the container 12 at a selected position if a maximum transverse cross-section of the buoy 30 is at a selected position, then a relatively minimal amount of other material can be present at the same location. In combination, the minimization of cross-sectional area of fractionated material and minimization of variation of axial orientation of the buoy in relation to an equilibrium interface results in minimization of variability of fractionated material volume near the interface.
The precision collection region 44, 92 (
According to various embodiments, an isolator 32, is coupled to the buoy 30. The combination of the isolator and buoy, according to various embodiments, can also be referred to as a separation assembly member. Exemplary isolators 82, 122, 170, 180, 190 are illustrated coupled to exemplary buoys 80, 120, 140, 160, 182, 192. The isolator 32, for example, provides a means for creating the collection compartment 52 and comprises one or more spacers 58, 60 to position the isolator 32 apart from the buoy 30 to create the collection compartment 52. A withdraw port 70 can be carried on the isolator 32 communicating with the withdraw port 27 and the collection port 50. The spacer 58, 60 can also serve as a conduit 68 between the collection port 50 and a withdraw or withdraw port 27. The withdraw port 27 serves as a structure for withdrawing the isolated or second fraction 310 from the collection compartment 52.
The isolator 32 can be configured from a material with a lower density than the buoy 30, such as a density of about 1.0 g/cc or less. A volume of the isolator 32 can be substantially less than a volume of the buoy 30. The isolator 32 can be configured so the isolator volume and the buoy volume combined below a selected equilibrium interface are greater than the isolator volume and the buoy volume combined above the equilibrium interface. As discussed above, an equilibrium interface can include a position relative to the platelet concentrate or buffy coat from a centrifuged whole blood sample, such as at or just below the platelet concentrate or buffy coat. By configuring the isolator 32 and buoy 30 with more volume below the equilibrium interface than above the equilibrium interface, the buoy 30 operates in a more repeatable manner even between a wide range in variations in compositions such as whole blood where the variability in density of a more dense fraction (e.g. red blood cells) is less than the variability in density of a less dense fraction (e.g. plasma). For example, the make up of a whole blood sample from one patient to the next can be markedly different.
Between individual patients, the density of the red blood cell or erythrocyte fraction of a whole blood sample can generally vary less than the density of a plasma or serum portion of a whole blood sample. Therefore, positioning a greater volume of the isolator and buoy within the denser fraction can assist in having highly repeatable and highly efficient collection or separation of a whole blood sample. The height H2 can be varied or selected to ensure a maximum or selected volume of the isolator and buoy are positioned within the denser fraction of the whole blood sample.
According to various embodiments, the isolator may include various features. An isolator 122 can be configured to move relative to a buoy 120, as illustrated in
An isolator 170 can include collection openings 174 (
The collection openings 174 can be sized to permit selected particles to pass yet sufficiently small so suspension fluid tension maintains adequate isolation of the collection compartment. The collection openings can also include various valves such as a duck bill or flapper bill which can open under certain conditions and close under others. A collection valve can be interconnected with any appropriate portion such as with a collection port 70 or passage 68.
The collection vent passage 67 through the isolator 32 equalizes pressure when fluid is withdrawn from the collection area 52. The spacer 58 can serve as a conduit for the collection vent passage 67, the collection port 50, or both. The collection valve communicates with the collection vent passage 67 to control collection vent passage 67 operation and close the collection vent passage 67 during re-suspension agitation. The collection vent tube 203 communicates with the collection vent passage 67 and air. The air can be the air above the collection area 52 (i.e. a portion of the suspension above the isolator 32 has been removed) or through an opening 205 in the container wall and generally through a sterile barrier (e.g. a sterile foam filter). The collection vent tube 203 allows removal of fractionated suspension in the collection compartment without the need to remove the fraction, such as plasma, above the isolator 32. Although, without a collection vent tube 203, the fraction above the isolator could be removed and the collection area could be vented to the area above the isolator.
Various embodiments further comprise a mechanical agitator 130 carried in a collection compartment 128 (for example
The isolator 122 is moveable relative to the buoy 120. The isolator 122 can be in an open position after centrifugation of the separation container. During removal of material from the collection compartment through the collection port 134, the isolator 122 can move in the direction indicated by arrow 123 toward the buoy 120 to decrease or close the volume of the collection compartment 128.
The buoy 30 can also be formed in a plurality of selectable sizes, having different dimensions, such as those illustrated in
A buoy 182, as illustrated in
A buoy 192, as illustrated in
The isolators 180, 190 can act substantially similar to the isolator 32, discussed above. The isolator 180, 190 can define an angle between an apex or the withdrawal port 70 and an outer edge of the isolators 180, 190. The upper surface of the isolators can include an angle to assist in directing a selected material, such as a platelet fraction of whole blood sample, to the collection area or surface 42 of the buoys 182, 192. Generally, the isolators 180, 190 can include a height or volume to substantially minimize the volume of the isolator 180, 190 relative to the buoys 182, 192. As discussed above, this can assist in positioning the buoys 182, 192 relative to a dense (e.g. red blood cell) fraction of a whole blood sample. The angle of the isolators 180, 190 and the height of the isolators 180, 190 can be selected to provide for a minimal distance of travel or least disturbance of a selected collected fraction of a material, such as a whole blood sample.
As discussed above, the buoy suspension fractionation system 10 can be used in a method of isolating a fraction from a suspension. The separation container 12 can be centrifuged for a period that is appropriate for the suspension. The buoy 30 in the separation container 12 is allowed to reach an equilibrium position within the formed fractions. Typically, the buoy moves from the separation container bottom to an equilibrium position within and/or between the fractions. In some embodiments, the buoy 30 is configured with the transverse dimension cross-sectional area of the buoy near the equilibrium interface to be substantially the buoy's maximum transverse cross-sectional area A1, as illustrated in
Particulates are concentrated using a guide surface 42, 90, 138, 152, 162 of the buoy that is inclined to an accumulation position near a perimeter of the buoy. The guide surface can be inclined relative to the buoy sidewall substantially throughout a length of the guide surface. The guide surface can be defined by or positioned near the top wall of the buoy.
The particulates are conveyed along the guide surface of the buoy to a collection space. The particulates can be conveyed along a substantially planar path to the collection space. According to various embodiments, however, the guide surface can also include multiple angles 42, 44 and 152, 154 and/or contours 96, 98. The particulates can be selected from the group consisting of platelets, stromal cells, white blood cells, or the like.
A desired fraction is withdrawn from the collection space through an access port. In some embodiments, the desired fraction can be withdrawn from the collection space by tipping the separation container and pouring the desired fraction out through an access port or out through the container top. This is especially true when only the buoy 30′, 30″, 30″′ is present (
In some embodiments, the method of isolating a fraction can further comprise isolating an isolated fraction in a collection compartment between the guide surface of the buoy 30, 80, 120, 140, 160, 180, 190 and an isolator 32, 82, 122, 142, 162, 182, 192 coupled to the buoy and withdrawing the isolated fraction through a withdraw port through the isolator.
The buoy suspension fractionation system can be used in a method of isolating and re-suspending particulates for withdrawal. The method begins by filling a separation container through an access port with a suspension. The separation container has a buoy with a tuned density and the suspension can contact the buoy.
The separation container can be centrifuged to cause the suspension to separate into fractions of varying densities. Centrifugation can occur for a period that is appropriate for the suspension, such as about five to about thirty minutes.
The buoy in the separation container is allowed to reach equilibrium within the fluid between two or more fractions. Typically the buoy moves from the separation container bottom to equilibrium within the fractions. In some embodiments, particulates can be concentrated using a guide surface of the buoy. The guide surface can be inclined to an accumulation position 44, 92 near a buoy perimeter location. According to various embodiments, the guide surface can be inclined relative to a buoy sidewall substantially throughout the length of the guide surface. The particulates can be conveyed along the guide surface of the buoy to a collection port. The particulates can be platelets, stromal cells, white blood cells, or the like.
A fraction is isolated in a collection compartment between the guide surface of the buoy and an isolator coupled to the buoy. In some embodiments, there can be a fraction 308 located above the isolator that can be withdrawn prior to withdrawing a first increment of the second fraction 310. In other embodiments, the collection vent tube 203 can eliminate the need to withdraw the fraction 308 located above the isolator prior to withdrawing the first increment of the second fraction 310.
Particulates within the isolated fraction can be re-suspended within the collection compartment by moving an agitator 130, 316 (
The re-suspended isolated fraction can be withdrawn from the collection compartment.
For illustration and for efficiency of use of the system, the various components can be included in a kit 320, illustrated in
Thus, embodiments of a buoy suspension fractionation system are disclosed. One skilled in the art will appreciate that the teachings can be practiced with embodiments other than those disclosed. The disclosed embodiments are presented for purposes of illustration and not limitation, and the invention is only limited by the claims that follow.
This application is a continuation of U.S. patent application Ser. No. 12/897,401 filed on Oct. 4, 2010, now U.S. Pat. No. 8,119,013, which is a divisional of U.S. patent application Ser. No. 12/101,594 filed on Apr. 11, 2008, now U.S. Pat. No. 7,806,276 issued on Oct. 5, 2010, which claims the benefit of U.S. Provisional Application No. 60/911,407 filed on Apr. 12, 2007. The disclosures of the above applications and patents are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
280820 | Hickson et al. | Jul 1883 | A |
593333 | Park | Nov 1897 | A |
1468313 | Lux | Sep 1923 | A |
1593814 | Vogel | Jul 1926 | A |
2722257 | Lockhart | Nov 1955 | A |
3013557 | Pallotta | Dec 1961 | A |
3159159 | Cohen | Dec 1964 | A |
3409165 | Creith | Nov 1968 | A |
3441143 | Kudlaty | Apr 1969 | A |
3453364 | Flodin et al. | Jul 1969 | A |
3469369 | Helmke | Sep 1969 | A |
3508653 | Coleman | Apr 1970 | A |
3545671 | Ross | Dec 1970 | A |
3583627 | Wilson | Jun 1971 | A |
3596652 | Winkelman | Aug 1971 | A |
3654925 | Holderith | Apr 1972 | A |
3706305 | Berger et al. | Dec 1972 | A |
3706306 | Berger et al. | Dec 1972 | A |
3723244 | Breillatt, Jr. | Mar 1973 | A |
3779383 | Ayres | Dec 1973 | A |
3785549 | Latham, Jr. | Jan 1974 | A |
3814248 | Lawhead | Jun 1974 | A |
3849072 | Ayres | Nov 1974 | A |
3850369 | Bull et al. | Nov 1974 | A |
3879295 | Glover et al. | Apr 1975 | A |
3887466 | Ayres | Jun 1975 | A |
3894952 | Ayres | Jul 1975 | A |
3896733 | Rosenberg | Jul 1975 | A |
3897337 | Ayres | Jul 1975 | A |
3897343 | Ayres | Jul 1975 | A |
3909419 | Ayres | Sep 1975 | A |
3929646 | Adler | Dec 1975 | A |
3931010 | Ayres et al. | Jan 1976 | A |
3931018 | North, Jr. | Jan 1976 | A |
3935113 | Ayres | Jan 1976 | A |
3937211 | Merten | Feb 1976 | A |
3941699 | Ayres | Mar 1976 | A |
3945928 | Ayres | Mar 1976 | A |
3951801 | Ayres | Apr 1976 | A |
3957654 | Ayres | May 1976 | A |
3962085 | Liston et al. | Jun 1976 | A |
3965889 | Sachs | Jun 1976 | A |
3972812 | Gresl, Jr. | Aug 1976 | A |
3982691 | Schlutz | Sep 1976 | A |
4001122 | Griffin | Jan 1977 | A |
4020831 | Adler | May 1977 | A |
4046699 | Zine, Jr. | Sep 1977 | A |
4055501 | Cornell | Oct 1977 | A |
4059108 | Latham, Jr. | Nov 1977 | A |
4066549 | Oeser et al. | Jan 1978 | A |
4077396 | Wardlaw et al. | Mar 1978 | A |
4088582 | Murty et al. | May 1978 | A |
4146172 | Cullis et al. | Mar 1979 | A |
4152270 | Cornell | May 1979 | A |
4154690 | Ballies et al. | May 1979 | A |
4159896 | Levine et al. | Jul 1979 | A |
4187979 | Cullis et al. | Feb 1980 | A |
4203840 | Stoeppler et al. | May 1980 | A |
4204537 | Latham, Jr. | May 1980 | A |
4225580 | Rothman et al. | Sep 1980 | A |
4269718 | Persidsky | May 1981 | A |
4294707 | Ikeda et al. | Oct 1981 | A |
4298598 | Schwarz et al. | Nov 1981 | A |
4300717 | Latham, Jr. | Nov 1981 | A |
4303193 | Latham, Jr. | Dec 1981 | A |
4314823 | Rich, Jr. et al. | Feb 1982 | A |
4322298 | Persidsky | Mar 1982 | A |
4362567 | Schwarz et al. | Dec 1982 | A |
4364832 | Ballies et al. | Dec 1982 | A |
4377572 | Schwarz et al. | Mar 1983 | A |
4379849 | Heimreid | Apr 1983 | A |
4411794 | Schwinn et al. | Oct 1983 | A |
4414976 | Schwarz et al. | Nov 1983 | A |
4416654 | Schoendorfer et al. | Nov 1983 | A |
4417981 | Nugent | Nov 1983 | A |
4424132 | Iriguchi et al. | Jan 1984 | A |
4427650 | Stroetmann et al. | Jan 1984 | A |
4427651 | Stroetmann et al. | Jan 1984 | A |
4442655 | Stroetmann et al. | Apr 1984 | A |
4443345 | Wells | Apr 1984 | A |
4446021 | Aufderhaar et al. | May 1984 | A |
4453927 | Sinko | Jun 1984 | A |
4453939 | Zimmerman et al. | Jun 1984 | A |
4464167 | Schoendorfer et al. | Aug 1984 | A |
4511662 | Baran et al. | Apr 1985 | A |
4537767 | Rothman et al. | Aug 1985 | A |
RE32089 | Blatt et al. | Mar 1986 | E |
4577514 | Bradley et al. | Mar 1986 | A |
4610656 | Mortensen | Sep 1986 | A |
4617009 | Ohlin et al. | Oct 1986 | A |
4627879 | Rose et al. | Dec 1986 | A |
4631055 | Redl et al. | Dec 1986 | A |
4632761 | Bowers et al. | Dec 1986 | A |
4639316 | Eldegheidy | Jan 1987 | A |
4650678 | Fuhge et al. | Mar 1987 | A |
4655211 | Sakamoto et al. | Apr 1987 | A |
4672969 | Dew | Jun 1987 | A |
4675117 | Neumann et al. | Jun 1987 | A |
4680025 | Kruger et al. | Jul 1987 | A |
4714457 | Alterbaum | Dec 1987 | A |
4735616 | Eibl et al. | Apr 1988 | A |
4735726 | Duggins | Apr 1988 | A |
4755300 | Fischel et al. | Jul 1988 | A |
4755301 | Bowers | Jul 1988 | A |
4770779 | Ichikawa et al. | Sep 1988 | A |
4776964 | Schoendorfer et al. | Oct 1988 | A |
4818291 | Iwatsuki et al. | Apr 1989 | A |
4818386 | Burns | Apr 1989 | A |
4828710 | Itoh et al. | May 1989 | A |
4832851 | Bowers et al. | May 1989 | A |
4844818 | Smith | Jul 1989 | A |
4846835 | Grande | Jul 1989 | A |
4850952 | Figdor et al. | Jul 1989 | A |
4853137 | Ersson et al. | Aug 1989 | A |
4871462 | Fischel et al. | Oct 1989 | A |
4874368 | Miller et al. | Oct 1989 | A |
4877520 | Burns | Oct 1989 | A |
4879031 | Panzani et al. | Nov 1989 | A |
4902281 | Avoy | Feb 1990 | A |
4909251 | Seelich et al. | Mar 1990 | A |
4915847 | Dillon et al. | Apr 1990 | A |
4917801 | Luderer et al. | Apr 1990 | A |
4928603 | Rose et al. | May 1990 | A |
4929242 | Desecki et al. | May 1990 | A |
4939081 | Figdor et al. | Jul 1990 | A |
4943273 | Pages et al. | Jul 1990 | A |
4946601 | Fiehler | Aug 1990 | A |
4957637 | Cornell | Sep 1990 | A |
4957638 | Smith | Sep 1990 | A |
4983157 | Pober et al. | Jan 1991 | A |
4983158 | Headley | Jan 1991 | A |
4985153 | Kuroda et al. | Jan 1991 | A |
5000970 | Shanbhag et al. | Mar 1991 | A |
5002571 | O'Donnell, Jr. et al. | Mar 1991 | A |
5019243 | McEwen et al. | May 1991 | A |
5024613 | Vasconcellos et al. | Jun 1991 | A |
5030215 | Morse et al. | Jul 1991 | A |
5030341 | McEwen et al. | Jul 1991 | A |
5039401 | Columbus et al. | Aug 1991 | A |
5045048 | Kaleskas et al. | Sep 1991 | A |
5047004 | Wells | Sep 1991 | A |
5053127 | Schoendorfer et al. | Oct 1991 | A |
5053134 | Luderer et al. | Oct 1991 | A |
5071570 | Shiraki et al. | Dec 1991 | A |
5080262 | Herold et al. | Jan 1992 | A |
5086784 | Levine et al. | Feb 1992 | A |
5100564 | Pall et al. | Mar 1992 | A |
5104375 | Wolf et al. | Apr 1992 | A |
5112484 | Zuk, Jr. | May 1992 | A |
5112490 | Turpen | May 1992 | A |
5131907 | Williams et al. | Jul 1992 | A |
5137832 | Levine et al. | Aug 1992 | A |
5141645 | Shiraki et al. | Aug 1992 | A |
5147290 | Jonsson et al. | Sep 1992 | A |
5152905 | Pall et al. | Oct 1992 | A |
5156613 | Sawyer | Oct 1992 | A |
5165938 | Knighton | Nov 1992 | A |
5171456 | Hwang et al. | Dec 1992 | A |
5173295 | Wehling et al. | Dec 1992 | A |
5178602 | Wells | Jan 1993 | A |
5185001 | Galanakis | Feb 1993 | A |
5190057 | Sarfarazi | Mar 1993 | A |
5190759 | Lindblad et al. | Mar 1993 | A |
5197985 | Caplan et al. | Mar 1993 | A |
5203825 | Haynes et al. | Apr 1993 | A |
5204537 | Bennet et al. | Apr 1993 | A |
5206023 | Hunziker et al. | Apr 1993 | A |
5207638 | Choksi et al. | May 1993 | A |
5217426 | Bacehowski et al. | Jun 1993 | A |
5217627 | Pall et al. | Jun 1993 | A |
5219328 | Morse et al. | Jun 1993 | A |
5226877 | Epstein | Jul 1993 | A |
5226914 | Caplan et al. | Jul 1993 | A |
5234608 | Duff | Aug 1993 | A |
5236604 | Fiehler | Aug 1993 | A |
5251786 | Sarrine | Oct 1993 | A |
5258126 | Pall et al. | Nov 1993 | A |
5260420 | Burnouf-Radosevich et al. | Nov 1993 | A |
5269927 | Fiehler | Dec 1993 | A |
5271852 | Luoma, II | Dec 1993 | A |
5279825 | Wehling et al. | Jan 1994 | A |
5281342 | Biesel et al. | Jan 1994 | A |
5290552 | Sierra et al. | Mar 1994 | A |
5290918 | Bui-Khac et al. | Mar 1994 | A |
5298171 | Biesel et al. | Mar 1994 | A |
5304372 | Michalski et al. | Apr 1994 | A |
5316674 | Pall et al. | May 1994 | A |
5318524 | Morse et al. | Jun 1994 | A |
5318782 | Weis-Fogh et al. | Jun 1994 | A |
5321126 | van Dommelen et al. | Jun 1994 | A |
5322620 | Brown et al. | Jun 1994 | A |
5330974 | Pines et al. | Jul 1994 | A |
5344752 | Murphy | Sep 1994 | A |
5354483 | Furse | Oct 1994 | A |
5370802 | Brown | Dec 1994 | A |
5372945 | Alchas et al. | Dec 1994 | A |
5376263 | Fischel | Dec 1994 | A |
5387187 | Fell et al. | Feb 1995 | A |
5393674 | Levine et al. | Feb 1995 | A |
5395923 | Bui-Khac et al. | Mar 1995 | A |
5403272 | Deniega et al. | Apr 1995 | A |
5405607 | Epstein | Apr 1995 | A |
5409833 | Hu et al. | Apr 1995 | A |
5411885 | Marx | May 1995 | A |
5417650 | Gordon | May 1995 | A |
5420250 | Lontz | May 1995 | A |
5443481 | Lee | Aug 1995 | A |
5454958 | Fiehler | Oct 1995 | A |
5456693 | Conston et al. | Oct 1995 | A |
5456885 | Coleman et al. | Oct 1995 | A |
5474687 | Van Vlasselaer | Dec 1995 | A |
5486359 | Caplan et al. | Jan 1996 | A |
5494578 | Brown et al. | Feb 1996 | A |
5494592 | Latham, Jr. et al. | Feb 1996 | A |
5501371 | Schwartz-Feldman | Mar 1996 | A |
5505685 | Antwiler | Apr 1996 | A |
5510102 | Cochrum | Apr 1996 | A |
5520885 | Coelho et al. | May 1996 | A |
5525477 | Hassouna | Jun 1996 | A |
5533518 | Vogler | Jul 1996 | A |
5560830 | Coleman et al. | Oct 1996 | A |
5575778 | Hardt et al. | Nov 1996 | A |
5577513 | Van Vlasselaer | Nov 1996 | A |
5585007 | Antanavich et al. | Dec 1996 | A |
5588958 | Cunningham et al. | Dec 1996 | A |
5589462 | Patat et al. | Dec 1996 | A |
5601727 | Bormann et al. | Feb 1997 | A |
5603845 | Holm | Feb 1997 | A |
5607579 | Latham, Jr. et al. | Mar 1997 | A |
5614106 | Payrat et al. | Mar 1997 | A |
5618663 | Delmas et al. | Apr 1997 | A |
5632895 | Tsukagoshi et al. | May 1997 | A |
5632905 | Haynes | May 1997 | A |
5641414 | Brown | Jun 1997 | A |
5641622 | Lake et al. | Jun 1997 | A |
5643192 | Hirsh et al. | Jul 1997 | A |
5645540 | Henniges et al. | Jul 1997 | A |
5646004 | Van Vlasselaer | Jul 1997 | A |
5648223 | Van Vlasselaer | Jul 1997 | A |
5649903 | Deniega et al. | Jul 1997 | A |
5663051 | Vlasselaer | Sep 1997 | A |
5674173 | Hlavinka et al. | Oct 1997 | A |
5707331 | Wells et al. | Jan 1998 | A |
5707647 | Dunn et al. | Jan 1998 | A |
5707876 | Levine | Jan 1998 | A |
5716616 | Prockop et al. | Feb 1998 | A |
5723331 | Tubo et al. | Mar 1998 | A |
5724988 | Dennehey et al. | Mar 1998 | A |
5733466 | Benebo et al. | Mar 1998 | A |
5733545 | Hood, III | Mar 1998 | A |
5736033 | Coleman et al. | Apr 1998 | A |
5738784 | Holm et al. | Apr 1998 | A |
5738796 | Bormann et al. | Apr 1998 | A |
5750025 | Holmes et al. | May 1998 | A |
5750658 | Coelho et al. | May 1998 | A |
5762798 | Wenthold et al. | Jun 1998 | A |
5785700 | Olson | Jul 1998 | A |
5786217 | Tubo et al. | Jul 1998 | A |
5788662 | Antanavich et al. | Aug 1998 | A |
5792344 | Holm | Aug 1998 | A |
5795489 | Holm et al. | Aug 1998 | A |
5795571 | Cederholm-Williams et al. | Aug 1998 | A |
5795751 | Apel | Aug 1998 | A |
5811094 | Caplan et al. | Sep 1998 | A |
5811151 | Hendriks et al. | Sep 1998 | A |
5817519 | Zelmanovic et al. | Oct 1998 | A |
5823986 | Peterson | Oct 1998 | A |
5824084 | Muschler | Oct 1998 | A |
5830359 | Knight et al. | Nov 1998 | A |
5833866 | Brown | Nov 1998 | A |
5834418 | Brazeau et al. | Nov 1998 | A |
5837150 | Langley et al. | Nov 1998 | A |
5840502 | Van Vlasselaer | Nov 1998 | A |
5860937 | Cohen | Jan 1999 | A |
5863892 | Stern et al. | Jan 1999 | A |
5865785 | Bischof | Feb 1999 | A |
5885239 | Headley et al. | Mar 1999 | A |
5889584 | Wardlaw | Mar 1999 | A |
5895346 | Wells et al. | Apr 1999 | A |
5899874 | Jonsson et al. | May 1999 | A |
5900245 | Sawhney et al. | May 1999 | A |
5906934 | Grande et al. | May 1999 | A |
5916557 | Berlowitz-Tarrant et al. | Jun 1999 | A |
5916743 | Lake et al. | Jun 1999 | A |
5918622 | Perez et al. | Jul 1999 | A |
5924972 | Turvaville et al. | Jul 1999 | A |
5934803 | Hutter | Aug 1999 | A |
5938621 | Kelly et al. | Aug 1999 | A |
5955032 | Kelly et al. | Sep 1999 | A |
5955436 | Kunkle, Jr. | Sep 1999 | A |
5958250 | Brown et al. | Sep 1999 | A |
5958253 | Holm et al. | Sep 1999 | A |
5980734 | Itoh et al. | Nov 1999 | A |
5985315 | Patat et al. | Nov 1999 | A |
6007811 | Sawyer et al. | Dec 1999 | A |
6010627 | Hood, III | Jan 2000 | A |
6020196 | Hu et al. | Feb 2000 | A |
6022306 | Dumont et al. | Feb 2000 | A |
6025201 | Zelmanovic et al. | Feb 2000 | A |
6027655 | Holm | Feb 2000 | A |
6049026 | Muschler | Apr 2000 | A |
6051146 | Green et al. | Apr 2000 | A |
6051147 | Bischof | Apr 2000 | A |
6053856 | Hlavinka | Apr 2000 | A |
6054122 | MacPhee et al. | Apr 2000 | A |
6063297 | Antanavich et al. | May 2000 | A |
6063624 | Kandler et al. | May 2000 | A |
6071421 | Brown | Jun 2000 | A |
6071422 | Hlavinka et al. | Jun 2000 | A |
6071423 | Brown et al. | Jun 2000 | A |
6090793 | Zimmermann et al. | Jul 2000 | A |
6096309 | Prior et al. | Aug 2000 | A |
6117425 | MacPhee et al. | Sep 2000 | A |
6123655 | Fell et al. | Sep 2000 | A |
6150163 | McPherson et al. | Nov 2000 | A |
6153113 | Goodrich et al. | Nov 2000 | A |
6183737 | Zaleske et al. | Feb 2001 | B1 |
6196987 | Holmes et al. | Mar 2001 | B1 |
6197325 | MacPhee et al. | Mar 2001 | B1 |
6200287 | Keller et al. | Mar 2001 | B1 |
6200606 | Peterson et al. | Mar 2001 | B1 |
6214338 | Antanavich et al. | Apr 2001 | B1 |
6221315 | Giesler et al. | Apr 2001 | B1 |
6245900 | Yamasaki et al. | Jun 2001 | B1 |
6264890 | Boehringer et al. | Jul 2001 | B1 |
6274090 | Coelho et al. | Aug 2001 | B1 |
6277961 | Hock et al. | Aug 2001 | B1 |
6280400 | Niermann | Aug 2001 | B1 |
6296602 | Headley | Oct 2001 | B1 |
6316247 | Katz et al. | Nov 2001 | B1 |
6322785 | Landesberg et al. | Nov 2001 | B1 |
6327491 | Franklin et al. | Dec 2001 | B1 |
6328765 | Hardwick et al. | Dec 2001 | B1 |
6342157 | Hood, III | Jan 2002 | B1 |
6351659 | Vilsmeier | Feb 2002 | B1 |
6355239 | Bruder et al. | Mar 2002 | B1 |
6368298 | Beretta et al. | Apr 2002 | B1 |
6368498 | Guilmette | Apr 2002 | B1 |
6398972 | Blasetti et al. | Jun 2002 | B1 |
6406671 | DiCesare et al. | Jun 2002 | B1 |
6410344 | Chung et al. | Jun 2002 | B1 |
6417004 | Brady et al. | Jul 2002 | B1 |
6440444 | Boyce et al. | Aug 2002 | B2 |
6444228 | Baugh et al. | Sep 2002 | B1 |
6464624 | Pages | Oct 2002 | B2 |
6471069 | Lin et al. | Oct 2002 | B2 |
6472162 | Coelho et al. | Oct 2002 | B1 |
6508778 | Verkaart et al. | Jan 2003 | B1 |
6516953 | DiCesare et al. | Feb 2003 | B1 |
6523698 | Dennehey et al. | Feb 2003 | B1 |
6544162 | Van Wie et al. | Apr 2003 | B1 |
6544727 | Hei | Apr 2003 | B1 |
6558341 | Swisher | May 2003 | B1 |
6596180 | Baugh et al. | Jul 2003 | B2 |
6623959 | Harris | Sep 2003 | B2 |
6629919 | Egozy et al. | Oct 2003 | B2 |
6638503 | Chitte et al. | Oct 2003 | B2 |
6676629 | Andrew et al. | Jan 2004 | B2 |
6719901 | Dolecek et al. | Apr 2004 | B2 |
6733471 | Ericson et al. | May 2004 | B1 |
6758978 | Bedell | Jul 2004 | B1 |
6777231 | Katz et al. | Aug 2004 | B1 |
6803022 | DiCesare et al. | Oct 2004 | B2 |
6811777 | Mishra | Nov 2004 | B2 |
6830762 | Baugh et al. | Dec 2004 | B2 |
6835353 | Smith et al. | Dec 2004 | B2 |
6835377 | Goldberg et al. | Dec 2004 | B2 |
RE38730 | Wells et al. | Apr 2005 | E |
6899813 | Dolecek et al. | May 2005 | B2 |
6905612 | Dorian et al. | Jun 2005 | B2 |
6911202 | Amir et al. | Jun 2005 | B2 |
RE38757 | Wells et al. | Jul 2005 | E |
7011644 | Andrew et al. | Mar 2006 | B1 |
7077273 | Ellsworth et al. | Jul 2006 | B2 |
7077827 | Greenfield | Jul 2006 | B2 |
7155288 | Soykan et al. | Dec 2006 | B2 |
7179391 | Leach et al. | Feb 2007 | B2 |
7195606 | Ballin | Mar 2007 | B2 |
7223346 | Dorian et al. | May 2007 | B2 |
7273886 | Olivero et al. | Sep 2007 | B2 |
7354515 | Coull et al. | Apr 2008 | B2 |
7374678 | Leach et al. | May 2008 | B2 |
7411006 | Shanbrom | Aug 2008 | B2 |
7470371 | Dorian et al. | Dec 2008 | B2 |
7531355 | Rodriguez et al. | May 2009 | B2 |
7553413 | Dorian et al. | Jun 2009 | B2 |
7845499 | Higgins et al. | Dec 2010 | B2 |
7914689 | Higgins et al. | Mar 2011 | B2 |
8048321 | Leach et al. | Nov 2011 | B2 |
8062534 | Higgins et al. | Nov 2011 | B2 |
20010009757 | Bischof et al. | Jul 2001 | A1 |
20020035820 | Farris | Mar 2002 | A1 |
20020076400 | Katz et al. | Jun 2002 | A1 |
20020082220 | Hoemann et al. | Jun 2002 | A1 |
20020090711 | Karlsson | Jul 2002 | A1 |
20020104808 | Blasetti et al. | Aug 2002 | A1 |
20020114775 | Pathak | Aug 2002 | A1 |
20020161449 | Muschler | Oct 2002 | A1 |
20020169408 | Beretta et al. | Nov 2002 | A1 |
20020172666 | Sacchi et al. | Nov 2002 | A1 |
20020182664 | Dolecek et al. | Dec 2002 | A1 |
20020192632 | Hei et al. | Dec 2002 | A1 |
20030033021 | Plouhar et al. | Feb 2003 | A1 |
20030033022 | Plouhar et al. | Feb 2003 | A1 |
20030050709 | Noth et al. | Mar 2003 | A1 |
20030050710 | Petersen et al. | Mar 2003 | A1 |
20030082152 | Hedrick et al. | May 2003 | A1 |
20030185803 | Kadiyala et al. | Oct 2003 | A1 |
20030191429 | Andrew et al. | Oct 2003 | A1 |
20030205538 | Dorian et al. | Nov 2003 | A1 |
20040013575 | Stevens et al. | Jan 2004 | A1 |
20040120942 | McGinnis et al. | Jun 2004 | A1 |
20040171146 | Katz et al. | Sep 2004 | A1 |
20040182395 | Brookman | Sep 2004 | A1 |
20040182788 | Dorian et al. | Sep 2004 | A1 |
20040182795 | Dorian et al. | Sep 2004 | A1 |
20040251217 | Leach et al. | Dec 2004 | A1 |
20050076396 | Katz et al. | Apr 2005 | A1 |
20050084961 | Hedrick et al. | Apr 2005 | A1 |
20050084962 | Simon | Apr 2005 | A1 |
20050109716 | Leach et al. | May 2005 | A1 |
20050130301 | McKay et al. | Jun 2005 | A1 |
20050153441 | Hedrick et al. | Jul 2005 | A1 |
20050153442 | Katz et al. | Jul 2005 | A1 |
20050186120 | Dorian et al. | Aug 2005 | A1 |
20050196393 | Shanbrom | Sep 2005 | A1 |
20050196874 | Dorian et al. | Sep 2005 | A1 |
20050247715 | Ellsworth et al. | Nov 2005 | A1 |
20050260174 | Fraser et al. | Nov 2005 | A1 |
20050260175 | Hedrick et al. | Nov 2005 | A1 |
20050282275 | Katz et al. | Dec 2005 | A1 |
20060051865 | Higgins et al. | Mar 2006 | A1 |
20060057693 | Simon | Mar 2006 | A1 |
20060083720 | Fraser et al. | Apr 2006 | A1 |
20060140923 | Evangelista et al. | Jun 2006 | A1 |
20060151384 | Ellsworth et al. | Jul 2006 | A1 |
20060175242 | Dorian et al. | Aug 2006 | A1 |
20060175244 | Dorian et al. | Aug 2006 | A1 |
20060178610 | Nowakowski | Aug 2006 | A1 |
20060196885 | Leach et al. | Sep 2006 | A1 |
20060243676 | Swift et al. | Nov 2006 | A1 |
20060273049 | Leach et al. | Dec 2006 | A1 |
20060273050 | Higgins et al. | Dec 2006 | A1 |
20060278588 | Woodell-May | Dec 2006 | A1 |
20070034579 | Dorian et al. | Feb 2007 | A1 |
20070036768 | Fraser et al. | Feb 2007 | A1 |
20070075016 | Leach | Apr 2007 | A1 |
20070208321 | Leach et al. | Sep 2007 | A1 |
20080011684 | Dorian et al. | Jan 2008 | A1 |
20080164204 | Hatamian et al. | Jul 2008 | A1 |
20080173593 | Coull et al. | Jul 2008 | A1 |
20080193424 | McKale et al. | Aug 2008 | A1 |
20080210645 | Coull et al. | Sep 2008 | A1 |
20080217263 | Higgins et al. | Sep 2008 | A1 |
20080217264 | Leach et al. | Sep 2008 | A1 |
20080217265 | Leach et al. | Sep 2008 | A1 |
20080268064 | Woodell-May | Oct 2008 | A1 |
20080269762 | Simon et al. | Oct 2008 | A1 |
20080283474 | Leach et al. | Nov 2008 | A1 |
20080306431 | Yoo | Dec 2008 | A1 |
20090014391 | Leach et al. | Jan 2009 | A1 |
20090018313 | Shanbrom | Jan 2009 | A1 |
20090101599 | Dorian et al. | Apr 2009 | A1 |
20090192528 | Higgins et al. | Jul 2009 | A1 |
20090220482 | Higgins et al. | Sep 2009 | A1 |
20090221075 | Dorian et al. | Sep 2009 | A1 |
20090236297 | Dorian et al. | Sep 2009 | A1 |
20090250413 | Hoeppner | Oct 2009 | A1 |
20090253566 | Chavarria | Oct 2009 | A1 |
20100055087 | Higgins et al. | Mar 2010 | A1 |
20100140182 | Chapman et al. | Jun 2010 | A1 |
20100206798 | Dorian et al. | Aug 2010 | A1 |
20100256595 | Leach et al. | Oct 2010 | A1 |
20100323870 | Leach et al. | Dec 2010 | A1 |
20100324450 | Leach et al. | Dec 2010 | A1 |
20110014705 | Leach et al. | Jan 2011 | A1 |
20110020196 | Grippi et al. | Jan 2011 | A1 |
20110021334 | Leach et al. | Jan 2011 | A1 |
20110036786 | Ellsworth | Feb 2011 | A1 |
20110056893 | Leach et al. | Mar 2011 | A1 |
20110065183 | Dorian et al. | Mar 2011 | A1 |
20110077596 | Higgins et al. | Mar 2011 | A1 |
20110168193 | Leach et al. | Jul 2011 | A1 |
20110192804 | Landrigan et al. | Aug 2011 | A1 |
20110251041 | Chavarria et al. | Oct 2011 | A1 |
20120015796 | Leach et al. | Jan 2012 | A1 |
Number | Date | Country |
---|---|---|
696278 | Jan 1999 | AU |
9103724 | Mar 1993 | BR |
1321138 | Aug 1993 | CA |
2182862 | Jun 1996 | CA |
2448415 | Dec 2002 | CA |
1074709 | Jul 1993 | CN |
56103 | Oct 1860 | DE |
1443359 | Nov 1968 | DE |
4202667 | May 1993 | DE |
090997 | Oct 1983 | EP |
0102773 | Mar 1984 | EP |
0109374 | May 1984 | EP |
0142339 | May 1985 | EP |
0244834 | Nov 1987 | EP |
0253198 | Jan 1988 | EP |
0295771 | Dec 1988 | EP |
0417818 | Mar 1991 | EP |
534178 | Mar 1993 | EP |
0534178 | Mar 1993 | EP |
0592242 | Apr 1994 | EP |
1005910 | Jun 2000 | EP |
1006360 | Jun 2000 | EP |
1289618 | Mar 2003 | EP |
1406492 | Apr 2004 | EP |
1427279 | Jun 2004 | EP |
1467746 | Oct 2004 | EP |
1509326 | Mar 2005 | EP |
1670315 | Jun 2006 | EP |
1716901 | Nov 2006 | EP |
854715 | Nov 1960 | GB |
60-053845 | Mar 1985 | JP |
60250014 | Dec 1985 | JP |
2036872 | Feb 1990 | JP |
02071747 | Mar 1990 | JP |
02129224 | Oct 2000 | JP |
2004-305439 | Nov 2004 | JP |
200598704 | Apr 2005 | JP |
2005098704 | Apr 2005 | JP |
2005524451 | Aug 2005 | JP |
2006-305365 | Nov 2006 | JP |
WO-8400905 | Mar 1984 | WO |
WO-8802259 | Apr 1988 | WO |
WO-9010031 | Sep 1990 | WO |
WO-9222312 | Dec 1992 | WO |
WO-9305067 | Mar 1993 | WO |
WO-9308904 | May 1993 | WO |
WO-9407548 | Apr 1994 | WO |
WO-9617871 | Jun 1996 | WO |
WO-9617871 | Jun 1996 | WO |
WO-9848938 | Nov 1998 | WO |
WO-0061256 | Oct 2000 | WO |
WO-0074713 | Dec 2000 | WO |
WO-0103756 | Jan 2001 | WO |
WO-0183068 | Nov 2001 | WO |
WO-0238610 | May 2002 | WO |
WO-02060925 | Aug 2002 | WO |
WO-02098566 | Dec 2002 | WO |
WO-03015800 | Feb 2003 | WO |
WO-03024215 | Mar 2003 | WO |
WO-03053362 | Jul 2003 | WO |
WO-03088905 | Oct 2003 | WO |
WO-03092894 | Nov 2003 | WO |
WO-03099412 | Dec 2003 | WO |
WO-2004009207 | Jan 2004 | WO |
WO-2004104553 | Dec 2004 | WO |
WO-2005034843 | Apr 2005 | WO |
WO-2007127834 | Nov 2007 | WO |
WO-2007142908 | Dec 2007 | WO |
WO-2009021257 | Feb 2009 | WO |
Entry |
---|
“Caps for Corning® and Costar® Plastic Labware,” Technical Bulletin. (Dec. 2008) Corning, Incorporated. |
“Cell Isolation Techniques, Methods and Materials, Working with Enzymes,” (2004) (9 pages) Worthington Biochemical Corp. |
“Cell Isolation Theory, Tissue Types,” (2004) (5 pages) Worthington Biochemical Corp. |
“Centrifuge Tubes” Corning Costar brochure. 1996/1997 Catalog pp. 76-77. |
“Clotalyst® Autologous Clotting Factor” brochure. (Aug. 15, 2008) Biomet Biologics. |
“Clotalyst® Autologous Clotting Factor. Would you like to have an autologous thrombin for rapid clotting and haemostasis?” Brochure. Biomet Biologics (Aug. 15, 2008). |
“Corning® 15 and 50 mL Centrifuge Tubes,” Life Sciences. (Jun. 2005) Corning Incorporated. |
“Cytori Celution Cell Concentrate Device,” Exhibit 14, 510(k) Summary, FDA approval K060482 (Sep. 28, 2006). |
“Frequently Asked Questions, 1. Kits, 2. Engzymes,” (2003) 3 pages Worthington Biochemical Corp. |
“Letter CryoSeal FS System. Vaccines, Blood & Biologics,” letter. (Jul. 26, 2007) FDA U.S. Food and Drug Administation. http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/ucm091631.htm (Web accessed Aug. 12, 2011). |
“MarrowStim™ Concentration Kit Peripheral Arterial Disease (PAD) Study” brochure. Web. Jul. 2, 2009 http://www.biomet.com/patients/clinical—recruitment—padstudy.cfm. |
“MarrowStim™ Concentration System,” brochure. Biomet Biologics Jun. 15, 2008. |
“Plasmax® Plasma Concentration System” brochure. (Jun. 15, 2008) Biomet® Biologics. |
“Prosys PRP Kit,” brochure Tozai Holdings, Inc. http://tozaiholdings.en.ec21.com/Prosys—PRP—Kit--5467051—5467061.html Printed from Web Aug. 24, 2011. |
“Prosys PRP Kit,” Tozai Holdings, Inc. EC21 Global B2B Marketplace http://www.ec21.com/product-details/Prosys-PRP-Kit--5467061.html Printed from Web Jul. 18, 2011. |
“ThermoGenesis Corp. to Supply Autologous Thrombin Kits to Biomet, Inc.,” PR Newslink: http:/tinyurl.com/4h3up. (Apr. 5, 2005) http://www.noblood.org/press-releases/2128-thermogenesis-corp-supply-autologous-thrombin-kits-biomet-inc [web accessed Sep. 27, 2011]. |
“Trypsinizing cells.” Bart's Cookbook, Web. Apr. 14, 2010. http://pingu.salk.edu/˜sefton/Hyper—protocols/trypsin.html. |
Anesthesiology, vol. 81, No. 4, pp. 1074-1077, Oct. 1994, Hiromasa Mitsuhata, M.D., et al., “An Anaphylactic Reaction to Topical Fibrin Glue”. |
Ann Thorac Surg, vol. 53, pp. 530-531, 1992, Mehmet C. Oz, M.D., et al., “Autologous Fibrin Glue From Intraoperatively Collected Platelet-Rich Plasma”. |
Ann Thorac Surg, vol. 56, pp. 387-389, 1993, Robert L. Quigley, M.D., et al., “Intraoperative Procurement of Autologous Fibrin Glue”. |
Badiavas, et al., “Treatment of Chronic Wounds With Bone Marrow-Derived Cells,” (Reprinted) Arch Dermatol. 139:510-516 (Apr. 2003). |
Bang, N.U., et al., “Plasma Protein Requirements for Human Platelet Aggregation” Ann. N.Y. Acad Sci, 201:280-299 (1972). |
Berguer, R., R. L. Staerkel, E. E. Moore, F. A. Moore, W. B. Galloway, and M. B. Mockus. “Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports.” J Trauma 31:3 (1991): 408-11. |
Berruyer, M., J. Amiral, P. Ffrench, J. Belleville, O. Bastien, J. Clerc, A. Kassir, S. Estanove, and M. Dechavanne. “Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors,” J Thorac Cardiovasc Surg 105: 5 (1993): 892-7. |
BioCUE™ Platelet Concentration System, Dec. 2010. (2 pages). |
Biopolymers, vol. 27, pp. 763-774, 1988, Gerald Marx, “Mechanism of Fibrin Coagulation Based on Selective, Cation-Driven, Protofibral Association”. |
Boomgaard, et al., “Pooled Platelet Concentrates Prepared by the Platelet-Rich-Plasma Method and Filtered with Three Different Filters and Stored for 8 Days.” Vox Sanq, vol. 68: 82-89, Feb. 1995. |
Brodke, et al., “Bone Grafts Prepared with Selective Cell Retention Technology Heal Canine Segmental Defects as Effectively as Autograft”, SCR-Enriched Bone Crafts Heal Canine Segmental Defects, Journal of Orthopaedic Research (May 2006) pp. 857-866. |
Casali, B., F. Rodeghiero, A. Tosetto, B. Palmieri, R. Immovilli, C. Ghedini, and P. Rivasi. “Fibrin glue from single-donation autologous plasmapheresis.” Transfusion 32:7 (1992): 641-3. |
CLOTALYST™ Automatic Clotting Factor, Would you like to have an autologous thrombin for rapid clotting and haemostatis?, brochure, Biomet Biologics, Inc., Feb. 2007 (12 pages). |
Collier, B.S. et al., “The pH Dependence of Quantitative Ristocetin-induced Platelet Aggregation: Theoretical and Practical Implications—A New Device for Maintenance of Platelet-Rich Plasma pH”, Hematology Service, Clinical Pathology Department, Clinical Center, National Institutes of Health, Bethesda, Md. 20014, Blood, vol. 47, No. 5 (May 1976). |
Connolly, “Injectable Bone Marrow Preparations to Stimulate Osteogenic Repair,” Clinical Orthopaedics and Related Research 313:8-18 (Apr. 1995). |
Connolly, John, M.D., et al. “Development of an Osteogenic Bone-Marrow Preparation.” The Journal of Bone and Joint Surgery, Incorporated. vol. 71-A, No. 5 (Jun. 1989) pp. 684-691. |
Dallari, et al., “In Vivo Study on the Healing of Bone Defects Treated with Bone Marrow Stromal Cells, Platelet-Rich Plasma, and Freeze-Dried Bone Allografts, Alone and in Combination,” Healing of Bone Defects, Journal of Orthopaedic Research (May 2006) pp. 877-888. |
De Ugarte, et al., “Comparison of Multi-Lineage Cells from Human Adipose Tissue and Bone Marrow,” Cells Tissues Organs 174:101-109 (2003). |
De Ugarte, et al., “Differential Expression of Stem Cell Mobilization-Associated Molecules on Multi-Lineage Cells from Adipose Tissue and Bone Marrow,” Immunology Letters 89:267-270 (2003). |
DelRossi, A. J., A. C. Cernaianu, R. A.Vertrees, C. J. Wacker, S. J. Fuller, J. Cilley Jr., and W. A. Baldino. “Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass.” J Thorac Cardiovasc Surg 100:2 (Aug. 1990): 281-6. |
DePalma, L., et al., “The preparation of fibrinogen concentrate for use as fibrin glue by four different methods.” Transfusion (1993) vol. 33, No. 9; pp. 717-720. |
DeUgarte, M.D., Daniel A., et al., “Future of Fat as Raw Material for Tissue Regeneration,” (Feb. 2003) pp. 215-219, Lippincott Williams & Wilkins, Inc. |
DiMuzio, Paul et al., “Development of a Tissue-Engineered Bypass Graft Seeded with Stem Cells,” Vasucular, vol. 14, No. 6, (2006) pp. 338-342, BC Decker, Inc. |
Drug Intelligence and Clinical Pharmacy, vol. 22, pp. 946-952, Dec. 1988, Dennis F. Thompson, et al., “Fibrin Glue: A Review of Its Preparation, Efficacy, and Adverse Effects as a Topical Hemostat”. |
Edlich, Richard F., George T. Rodeheaver, and John G. Thacker. “Surgical Devices in Wound Healing Management.” In Wound Healing: Biochemical & Clinical Aspects,ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 581-600. 1st ed., vol. Philadelphia: W.B. Saunders Company, 1992. |
Eppley, et al., “Platelet Quantification and Growth Factor Analysis from Platelet-Rich Plasma: Implications for Wound Healing,” Plastic and Reconstructive Surgery, 114(6):1502-1508 (Nov. 2004). |
Epstein, G. H., R. A. Weisman, S. Zwillenberg, and A. D. Schreiber. “A new autologous fibrinogen-based adhesive for otologic surgery.” Ann Otol Rhinol Laryngol 95 (May 25-26, 1985) 40-5. |
Fibrostik™ Plasma Concentrator, Attention Operating Surgeon, Cell Factor Technologies, Inc., Jul. 2003. |
First clinical results: Kuderma, H. and Helene Matras. “Die klinische Anwendung der Klebung van Nervenanastomosen mit Gerinnungssubstanzen bei der Rekonstruction verletzter peripherer Nerven.” Wein Klin Wochenschr 87 (Aug. 15, 1975): 495-501. |
Floryan, K. et al. “Home Study Program: Intraoperative Use of Autologous Platelet-Rich and Platelet-Poor Plasma for Orthopedic Surgery Patients” vol. 80, No. 4 (Oct. 2004) p. 667-674. |
Frasier, John K., et al., “Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytes,” Nature Clinical Practice Cardiovascular Medicine, vol. 3, Supplement 1 (Mar. 2006) pp. S33-S37. |
Friesen, M.D., Robert, et al. “Blood Conservation During Pediatric Cardiac Surgery: Ultrafiltration of the Extracorporeal Circuit Volume After Cardiopulmonary Bypass.” Anesth. Analg 1993: 77-702-7. |
Galois, et al., “Cartilage Tissue Engineering: State-of-the-Art and Future Approaches,” Pathol Biol (Paris), 53(10), Dec. 2005. |
Gibble, J. W. and P. M. Ness. “Fibrin glue: The perfect operative sealant?” Transfusion 30 (1990): 741-7. |
Gimble, Jeffrey M., “Adipose-Derived Stem Cells for Regenerative Medicine,” Circulation Research (May 11, 2007) pp. 1249-1260, American Heart Association, Inc. |
Gomillion, Cheryl T., et al., “Stem cells and adipose tissue engineering,” Biomaterials 27, Science Direct (2006) pp. 6052-6063, Elsevier. |
GPS® III System, GPS® III Platelet Separation System, Leadership through Technology , brochure, Jul. 2007 (8 sheets). |
GPS® System, “GPS® Platelet Concentrate System,” Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (Feb. 29, 2004) (9 pages). |
GPS® System, “Shoulder Recovery with the GPS® Platelet Concentrate System, Rotator Cuff Surgical Techniques,” brochure, Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) 6 pages. |
GPS® System, “Shoulder Recovery with the GPS® Platelet Concentrate System, Rotator Cuff Surgical Techniques,” Cell Factor Technologies, Inc., Biomet Orthopaedics, Inc., (2004) 3 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005. |
GPS® II System, Gravitational Platelet Separation System, “Accelerating the Body's Natural Healing Process,” Biomet Biologics (Jul. 15, 2006) 16 pages. |
GPS® II System, Gravitational Platelet Separation System, “Accelerating the Body's Natural Healing Process,” Cell Factor Technologies, Inc., Biomet Europe (2005) 16 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005. |
GPS® II System, Gravitational Platelet Separation System, “User Manual,” Cell Factor Technologies, Inc., Biomet Europe [date unknown] 13 pages, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005. |
Grove, et al., “Plasticity of Bone Marrow-Derived Stem Cells,” Stem Cells: Concise Review, 22, Jan. 2004. |
Guilak, Frank, et al., “Adipose-derived adult stem cells for cartilage tissue engineering,” Biorheology 41 (2004) pp. 389-399, IOS Press. |
Harris, E.L.V. Concentration of the Extract. In. Protein Purification Methods: A Practical Approach Harris, E.L.V.; Angal, S.; Editors. (1989) Publisher: (IRL Press, Oxford, UK), pp. 67-69. |
Hartman, A. R., D. K. Galanakis, M. P. Honig, F. C. Seifert, and C. E. Anagnostopoulos. “Autologous whole plasma fibrin gel. Intraoperative procurement.” Arch Surg 127 (Mar. 1992): 357-9. |
Harvest SmartPrep PRP-20 Procedure Pack, “Instructions for Use” (date unknown). |
Harvest Technologies brochure, SmartPrep2 (2002). |
Hattori, et al., “Osteogenic Potential of Human Adipose Tissue-Derived Stromal Cells as an Alternative Stem Cell Source,” Cells Tissues Organs (2004) 178:2-12 Karger. |
Haynesworth, S.E. et al. “Mitogenic Stimulation of Human Mesenchymal Stem Cells by Platelet Releasate Suggests a Mechanism for Enhancement of Bone Repair by Platelet Concentrate” 48th Annual Meeting of the Orthopaedic Research Society Poster No. 0462 (2002). |
Hennis, H. L., W. C. Stewart, and E. K. Jeter. “Infectious disease risks of fibrin glue [letter].” Ophthalmic Surg 23 (Sep. 1992): 640. |
Hernigou, et al., “Percutaneous Autologous Bone-Marrow Grafting for Nonunions. Influence of the Number and Concentration of Progenitor Cells,” Journal of Bone & Joint Surgery, 87-A(7):1430-1437 (Jul. 2005). |
Hom, D., et al. “Promoting Healing with Recombinant Human Platelet-Derived Growth Factor-BB in a Previously Irradiated Problem Wound.” The Laryngoscope, vol. 113 (pp. 1566-1671) Sep. 2003. |
Hood, Andrew G., et al., “Perioperative Autologous Sequestration III: A New Physiologic Glue with Wound Healing Properties,” (Jan. 1993) vol. 14 pp. 126-129. |
International Preliminary Examination Report and Written Opinion issued Aug. 31, 2010 for PCT/US2009/035564 claiming benefit of U.S. Appl. No. 61/078,178, filed Jul. 3, 2008, which priority is also claimed of said provisional case by U.S. Appl. No. 12/395,085, filed Feb. 27, 2009. |
International Preliminary Report on Patentability and Written Opinion mailed Oct. 13, 2011 for PCT/US2010/029957 which claims benefit of U.S. Appl. No. 12/417,789, filed Apr. 3, 2009. |
International Preliminary Report on Patentability completed Aug. 13, 2009 for PCT/US2008/004687 claiming benefit of U.S. Appl. No. 60/911,407, filed Apr. 12, 2007. |
International Preliminary Report on Patentability mailed Jan. 26, 2012 for PCT/US2010/041942 claiming benefit of U.S. Appl. No. 12/504,413, filed Jul. 16, 2009. |
International Search Report and Written Opinion mailed Aug. 9, 2011 for PCT/US2011/031954 claiming benefit of U.S. Appl. No. 12/758,127, filed Apr. 12, 2010. |
International Search Report and Written Opinion mailed Jul. 2, 2008 for International Application No. PCT/US2008/004687 which claims priority to U.S. Appl. No. 60/911,407, filed Apr. 12, 2007. |
International Search Report and Written Opinion mailed Jul. 3, 2009 for PCT/US2009/035564 claiming benefit of U.S. Appl. No. 61/078,178, filed Jul. 3, 2008. |
International Search Report and Written Opinion mailed Jul. 30, 2010 for PCT/US2010/029957 which claims benefit of U.S. Appl. No. 12/417,789, filed Apr. 3, 2009. |
International Search Report and Written Opinion mailed Nov. 7, 2011 for PCT/US2011/045290 claiming benefit of U.S. Appl. No. 12/846,944, filed Jul. 30, 2010. |
International Search Report and Written Opinion mailed Oct. 8, 2010 for PCT/US2010/041942 claiming benefit of U.S. Appl. No. 12/504,413, filed Jul. 16, 2009. |
International Search Report for International Application No. PCT/US/0316506 mailed Oct. 13, 2003 which claims benefit of U.S. Appl. No. 60/383,013, filed May 24, 2002. |
International Search Report for International Application No. PCT/US2007/012587 mailed Nov. 6, 2007 which claims benefit of U.S. Appl. No. 11/441,276, filed May 25, 2006. |
Ishida, et al., “Platelet-Rich Plasma With Biodegradable Gelatin Hydrogel Promotes Rabbit Meniscal Tissue Regeneration,” 52nd Annual Meeting of the Orthopaedic Research Society Paper No. 1035, 1 page (2006). |
Jackson, C. M. and Y. Nemerson. “Blood coagulation.” Annu Rev Biochem 49 (1980): 765-811). |
Jayadev, Suprya. “Trypsinization of Adherent Cells.” Aug. 8, 1991. Web. Apr. 14, 2010 http://www.duke.edu/web/ceramide/protocols/0005.html. |
Johnstone, et al., “Autologous Mesenchymal Progenitor Cells in Articular Cartilage Repair”, Clinical Orthopaedics and Related Research 367S:S156-S162 (Oct. 1999). |
Jorgensen, et al., “Stem Cells for Repair of Cartilage and Bone: The Next Challenge in Osteoarthritis and Rheumatoid Arthritis,” Annals of Rheumatic Diseases, Aug. 2000. |
Journal of Oral Maxillofacial Surgery, vol. 43, pp. 605-611, Helene Matras, M.D., “Fibrin Seal: The State of the Art” (1985). |
Karpatkin, S., “Heterogeneity of Human Platelets. VI., Correlation of Platelet Function with Platelet Volume”, Blood, vol. 51, No. 2 (Feb. 1978). |
Kjaergard, H. K,, U. S. Weis-Fogh, H. Sorensen, J. Thiis, and I. Rygg. “A simple method of preparation o£ autologous fibrin glue by means of ethanol.” Surg Gynecol Obstet 175 (1992): 72-3. |
Kjaergard, H. K., Fogh Us Weis, and J. J. Thiis. “Preparation of autologous fibrin glue from pericardial blood.” Ann Thorac Sur 55 (1993): 543-4. |
Kumar, Vijay et al. “Stability of Human Thrombin Produced From 11 ml of Plasma Using the Thrombin Processing Device,” Journal of American Society of Extra-Corporeal Technology. JECT: Mar. 2005:37; 390-395. |
Kumar, Vijay et al. “Whole Blood Thrombin: Development of a Process for Intra-Operative Production of Human Thrombin.” Journal of American Society of Extra-Corporeal Technology. JECT: Apr. 2007; 39:18-23. |
Kumar, Vijay et al., “Autologous Thrombin: Intraoperative Production From Whole Blood.” Journal of American Society of Extra-Corporeal Technology. JECT: Apr. 2008; 40:94-98. |
Laryngoscope vol. 99, pp. 974-976, Sep. 1989, Kyosti Laitakari, M.D., et al., “Autologous and Homologous Fibrinogen Sealants: Adhesive Strength”. |
Laryngoscope, vol. 95, pp. 1074-1076, Sep. 1985, Karl H. Siedentop, M.D., et al., “Autologous Fibrin Tissue Adhesive”. |
Laryngoscope, vol. 96, pp. 1062-1064, Oct. 1986, Karl H. Siedentop, M.D., et al., “Extended Experimental and Preliminary Surgical Findings with Autologous Fibrin Tissue Adhesive Made from Patient's Own Blood”. |
Lasher, Lisa, M.D., “My Experience with PRP,” PowerPoint presentation, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005. |
Lendeckel, Stefan, et al., “Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report,” Journal of Cranio-Maxillofacial Surgery (2004) European Association for Cranio-Maxillofacial Surgery. |
Lerner, R. and N. S. Binur. “Current status of surgical adhesives.” J Surg Res 48 (Feb. 1990): 165-81. |
Longas, Maria O., “An Improved Method for the Purification of Human Fibrinogen.” J. Biochem (1980) vol. 11, pp. 559-564. |
Lu, et al., “Bone Marrow Mesenchymal Stem Cells: Progress in Bone/Cartilage Defect Repair,” 19(1), Jan. 2002. |
Marrowstim Concentration System, Biomet Biologics, Inc., 20 pages. (REV Feb. 15, 2008). |
Marx, Gerard, et al., “Heat Denaturation of Fibrinogen to Develop a Biomedical Matrix.” Journal of Biomedical Materials Research Part B: Applied Biomaterials (Apr. 2007) pp. 49-57. |
Masri, Marwan A., et al. “Isolation of Human Fibrinogen of High Purity and in High Yield Using Polyethylene Glycol 1000.” Thromb Haemostas (Struttgart) (1983) vol. 49 (2); pp. 116-119. |
Matras, Helene, H. P. Dinges, H. Lassmann, and B. Mamoli. “Zur nahtlosen interfaszikularen Nerventransplantation im Tierexperiment.” Wein Med Woschtr 122:37 (1972): 517-523. |
Minntech® Filtration Technologies Group, “Hemocor HPH® Hemoconcentrator,” Minntech Corporation (2004); http://www.minntech.com/ftg/products/hph/index.html, printed Jul. 15, 2004 (2 pages). |
Minntech® Filtration Technologies Group, “Medical Applications: Blood Filtration” Minntech Corporation (2004); http://www.minntech.com/ftg/industries/medical/blood—filter.html, printed Jul. 15, 2004 (1 page). |
Minntech® Filtration Technologies Group, “Renaflo® II Hemofilter,” Minntech Corporation (2004); http://www.minntech.com/ftg/products/renaflo/index.html, printed Jul. 15, 2004 (2 pages). |
Molnar, Amy, “Stem Cells from Muscles Can Repair Cartilage, Study Finds Genetically Engineered Muscle-Derived Stem Cells Improved Cartilage Repair in Rats”, American College of Rheumatology, (2005). |
Moretz, W., Jr., J Shea Jr., J. R. Emmett, and J Shea. “A simple autologous fibrinogen glue for otologic surgery.” Otolaryngol Head Neck Surg 95 (Jul. 1986): 122-4. |
Nakagami, Hironori, et al., “Novel Autologous Cell Tehrapy in Ischemic Limb Disease Through Growth Factor Secretion by Cultured Adipose Tissue-Derived Stromal Cells,” Angiogenesis by Adipose Tissue-Derived Cells, (Dec. 2005) pp. 2542-2547, American Heart Association, Inc. |
Nathan, Suresh,, et al., “Cell-Based Therapy in the Repair of Osteochondral Defects: A Novel Use for Adipose Tissue,” Tissue Engineering, vol. 9, No. 4 (2003) pp. 733-744 Mary Ann Liebert, Inc. |
Nilsson, et al., “Bone Repair Induced by Bone Morphogenetic Protein in Ulnar Defects in Dogs,” The Journal of Bone and Joint Surgery, vol. 68 B., No. 4, Aug. 1986. |
Notice of Allowance mailed Mar. 24, 2011 for U.S. Appl. No. 12/101,586. |
Notice of Allowance mailed May 27, 2010 for U.S. Appl. No. 12/101,594, filed Apr. 11, 2008. |
Notice of Allowance mailed Oct. 18, 2011 for U.S. Appl. No. 12/897,401. |
Office Action (Final) mailed Mar. 18, 2010 for U.S. Appl. No. 12/101,594, filed Apr. 11, 2008. |
Office Action mailed Feb. 3, 2011 for U.S. Appl. No. 12/101,586, filed Apr. 14, 2008. |
Office Action mailed Nov. 16, 2010 for U.S. Appl. No. 12/897,401 claiming benefit of U.S. Appl. No. 12/101,594, filed Apr. 11, 2008. |
Office Action mailed Oct. 16, 2009 for U.S. Appl. No. 12/101,594, filed Apr. 11, 2008. |
Office Action mailed Sep. 20, 2010 for U.S. Appl. No. 12/101,586, filed Apr. 14, 2008. |
Orphardt, Charles E., “Denaturation of Proteins,” Virtual Chembook, Elmhurst College (2003) 3 pages. http://www.elmhurst.edu/˜chm/vchembook/568denaturation.html (web accessed Mar. 9, 2011). |
Otolaryngologic Clinics of North America, vol. 27, No. 1, pp. 203-209, Feb. 1994, Dean M. Toriumi, M.D., et al., “Surgical Tissue Adhesives in Otolaryngology—Head and Neck Surgery”. |
Parker, Anna M., et al., Adipose-derived stem cells for the regeneration of damaged tissues, Expert Opinion, Cell- & Tissue-based Therapy, Expert Opin. Biol. Ther. (2006) pp. 567-578 Informa UK Ltd. |
Planat-Bénard, V., et al., “Spontaneous Cardiomyocyte Differentiation From Adipose Tissue Stroma Cells,” Adipose-Derived Cell Cardiomyocyte (Feb. 6, 2004) pp. 223-229 American Heart Association, Inc. |
Ponticiello, Michael S., “A Rapid Technique for the Isolation and Concentration of Stem Cells from Human Bone Marrow”, Cell Factor Technologies, Inc. (2006) 2 pages. |
Rangappa, Sunil, M.D., “Transformation of Adult Mesenchymal Stem Cells Isolated From the Fatty Tissue Into Cardiomyocytes,” Adult Stem Cells Transformed into Cardiomyoctyes, (2003) pp. 775-779 Ann Thorac Surg. |
Rigotti, M.D., et al, “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells,” Plastic and Reconstructive Surgery, Breast, PRS Journal vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Apr. 15, 2007) pp. 1409-1422. |
Rubin, M.D., et al, “Clinical Treatment of Radiotherapy Tissue Damage by Lipoaspirate Transplant: A Healing Process Mediated by Adipose-Derived Adult Stem Cells,” Plastic and Reconstructive Surgery, Discussion vol. 119, No. 5, Stem Cell Therapy for Angiogenesis, (Apr. 15, 2007) pp. 1423-1424. |
Sanal, M. “Does fibrin glue cause foreign body reactions? [letter].” Eur J Pediatr Surg 3 (1992): 190 (1 page). |
Sanal, M., H. Dogruyol, A. Gurpinar, and O. Yerci. “Does fibrin glue cause foreign body reactions?” Eu r J Pediatr Surg 2 (1992): 285-6. |
Schmidt, K.G., et al., “Labelling of Human and Rabbit Platelets with Indium-Oxine Complex”, 23:97-106 (1979). |
Schmidt, K.G., et al., “Preparation of Platelet Suspensions from Whole Blood in Buffer”, Scand. J. Hoemato, 23:88-96 (1979). |
Schäffler, Andreas, et al., “Concise Review: Adipose Tissue-Derived Stromal Cells—Basic and Clinical Implications for Novel Cell-Based Therapies,” Tissue-Specific Stem Cells, Stem Cells® (Apr. 10, 2007) pp. 818-827 AlphaMed Press. |
Semple, Elizabeth, PhD, et al. “Quality of Thrombin Produced From the Patient's Own Plasma Using the TPD™, A New Thrombin-Processing Device.” Journal of American Society of Extra-Corporeal Technology. JECT: 2005; 37:196-200. |
Sierra, D. H. “Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications.” J Biomater Appl 7 (Apr. 1993): 309-52. |
Sigma-Aldrich® Alkaline Phosphatase (Procedure No. 85), drug fact sheet, (2003) pp. 1-2, Sigma-Aldrich, Inc. |
Silver, Frederick H., et al., “Review Preparation and use of fibrin glue in surgery.” Biomaterials 16 (1995) pp. 891-903. |
Solem, Jan Otto, et al., “Hemoconcentration by Ultrafiltration During Open-Heart Surgery,” Scand J Thor Cardiovasc Surg 22:271-274, 1988. |
Sutton, Robin G., et al. “Comparison of Three Blood-Processing Techniques During and After Cardiopulmonary Bypass.” Ann Thorac Surg (1993) vol. 56; pp. 941-943. |
Swift, Mathew J., et al., “Characterization of Growth Factors in Platelet Rich Plasma,” 1-Cell Factor Technologies, http://www.cellfactortech.com/global—products.cfm, printed Sep. 16, 2005. |
Symphony II Platelet Concentrate System/PCS brochure; “Increasing bone graft bioactivity through reproducible concentrations of natural growth factors,” DePuy (Jan. 2003). |
Takahashi, Kazutoshi et al., “Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors,” Cell, (Nov. 30, 2007) pp. 1-12, Elsevier Inc. |
The American Journal of Surgery, vol. 168, pp. 120-122, Aug. 1994, Roy L. Tawes, Jr., M.D., et al., “Autologous Fibrin Glue: The Last Step in Operative Hemostatis”. |
The American Surgeon, vol. 55, pp. 166-168, Mar. 1989, William D. Spotnitz, M.D., et al., “Successful Use of Fibrin Glue During 2 Years of Surgery at a University Medical Center”. |
The Sports Medicine Center, “Knee Cartilage Implantation”, Carticel™, “Autologous Cultured Chondrocyte Implantation”, http://www.orthoassociates.com/carticel.htm (printed Apr. 6, 2006). |
The Stone Clinic, “Platelet Rich Plasma (PRP)”, web site printed May 2006. |
Weis-Fogh, U. S. “Fibrinogen prepared from small blood samples for autologous use in a tissue adhesive system.” Eur Surg Res 20 (1988): 381-9. |
Weisman, MD., Robert A., “Biochemical Characterization of Autologous Fibrinogen Adhesive,” Laryngoscope 97: Oct. 1987; pp. 1186-1190. |
Wiseman, David M., David T. Rovee, and Oscar M. Alverez. “Wound Dressings: Design and Use.” In Wound Healing: Biochemical & Clinical Aspects,ed. I. Kelman Cohen, Robert F. Diegelmann, and William J. Lindblad. 562-580. 1st ed., vol. Philadelphia: W. B. Saunders Company, 1992. |
Woodell-May, et al., “Producing Accurate Platelet Counts for Platelet Rich Plasma: Validation of a Hematology Analyzer and Preparation Techniques for Counting,” Scientific Foundation, Journal of Carniofacial Surgery 16(5):749-756 (Sep. 2005). |
Written Opinion of the International Preliminary Examining Authority mailed Mar. 17, 2009 for International Application No. PCT/US2008/004687 which claims priority to U.S. Appl. No. 60/911,407, filed Apr. 12, 2007. |
Yoon, Eulsik, M.D., Ph.D., et al., “In Vivo Osteogenic Potential of Human Adipose-Derived Stem Cells/Poly Lactide-Co-Glycolic Acid Constructs for Bone Regneration in a Rat Critical-Sized Calvarial Defect Model,” Tissue Engineering, vol. 13, No. 3 (2007) pp. 619-627 Mary Ann Liebert, Inc. |
Zhang, Duan-zhen, et al., “Transplantation of autologous adipose-derived stem cells ameliorates cardiac function in rabbits with myocardial infarction,” Chinese Medical Journal, vol. 120, No. 4 (2007) pp. 300-307 General Hospital of Shenyang Military Region, Shenyang, China. |
Zuk, Patricia A., Ph.D., “Multilineage Cells from Human Adipose Tissue: Implications for Cell-Based Therapies,” Tissue Engineering, vol. 7, No. 2, (2001) pp. 211-228 Mary Ann Liebert, Inc. |
Japan Office Action mailed Jan. 22, 2013 for Japan Application No. 2010-503066. |
Number | Date | Country | |
---|---|---|---|
20120145652 A1 | Jun 2012 | US |
Number | Date | Country | |
---|---|---|---|
60911407 | Apr 2007 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12101594 | Apr 2008 | US |
Child | 12897401 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12897401 | Oct 2010 | US |
Child | 13400188 | US |